Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of topotecan + lapatinib in platinum-treated recurrent ovarian, fallopian tube, or peritoneal cancer
2007-005706-44Phase 2Active
- Sponsor
- Centre François Baclesse
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of topotecan and lapatinib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Centre François Baclesse. Primary endpoint: Overall response rate. Started Nov 2007; status: active.
02
Drugs
topotecanlapatinib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2007-005706-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005706-44.